| 000 | 03502cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032853.0 | ||
| 008 | 211128s2021 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.28.M.Sc.2021.Ab.A | ||
| 100 | 0 | _aAbeer Shehata Mohamed | |
| 245 | 1 | 0 |
_aAssociation of plasminogen activator inhibitor (PAI) gene polymorphism and the severity of sickle cell disease SCD / _cAbeer Shehata Mohamed ; Supervised Rasha Abdelraouf Abdelaziz , Iman Abdelmohsen Shaheen , Mohamed Abdallah Abdelmegied Abdallah |
| 246 | 1 | 5 | _aرابطة تعدد الأشكال الجينية للبلازمينوجين المنشط و شدة مرض فقر الدم المنجلى |
| 260 |
_aCairo : _bAbeer Shehata Mohamed , _c2021 |
||
| 300 |
_a185 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics | ||
| 520 | _aIntroduction: Sickle cell disease (SCD) comprises a group of hemolytic anemias characterized by a complex pathophysiology. The clinical manifestations of SCD result from chronic hemolytic anemia and the development of vaso-occlusive events. An increased risk for arterial thrombosis has been associated with low fibrinolytic activity related to raised plasma levels of plasminogen activator inhibitor 1 (PAI-1). Objective: To evaluate the incidence of plasminogen activator inhibitor 1 polymorphism 4G/5G (-675 pb 4G/5G) in chromosome (7q22.1 - rs1799889) among a group of Egyptian sickle cell disease pediatric patients and its relation to clinical and laboratory presentation of the studied patients. Patients and methods: This is a cross-sectional study that was carried out on 105 Sickle cell disease patients from Hematology outpatient{u2019}s clinic and hematology department of Cairo University Children{u2019}s Hospital. Detailed history, physical examination, and laboratory investigationswere documented.Blood samples was collected and DNA extracted according to standard protocols.The PAI-1 4G/5G polymorphism was evaluated.Results: Fifty-eight % of the study patients were more males (58.1%)and the highest density of patients were living in Giza (41%). The percentage of patients with SS phenotype was higher (54.4%). Anemia was the most common presentation of SCD (56.2%) and all patients had VOC as a complication of SCD. According to severity patients were more likely to have moderate to severe disease (34.3% & 37.1%). The wild form of PAI-1 gene polymorphism (4G/4G) was the most common among patients with SCD. When comparing the three different type of PAI-1 gene polymorphism we found that a higher number of patients with the homozygous form (5G/5G) had leg ulcers (P = 0.049) and elevated liver enzymes (P = 0.006), and a higher number of patients with heterozygous form (4G/5G) had pulmonary hypertension and LV dilatation (P = 0.028),while the highest number of abnormal TCD was in the wild form (4G/4G), but with no statistical significant (p value= 0,076) | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aPAI-1 | |
| 653 | 4 | _aPolymorphism | |
| 653 | 4 | _aSCD | |
| 700 | 0 |
_aIman Abdelmohsen Shaheen , _eSupervisor |
|
| 700 | 0 |
_aMohamed Abdallah Abdelmegied Abdallah , _eSupervisor |
|
| 700 | 0 |
_aRasha Abdelraouf Abdelaziz , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aShimaa _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c83327 _d83327 |
||